Paper Details

  1. Home
  2. Paper Details

Death Associated With Nadolol for Infantile Hemangioma: A Case for Improving Safety.

Author: BaumannTravis, LeRoyJenna, McGillisEric

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case report describes a 10-week-old girl who died after being treated with nadolol for infantile hemangioma, highlighting potential risks associated with nadolol in infants.
Paper Details　
Original Abstract of the Article :
Nadolol is a β-adrenergic antagonist that has been shown to be efficacious in the treatment of infantile hemangioma. It has been suggested that this drug may have fewer side effects compared with the gold standard therapy, propranolol, because it does not exhibit membrane-stabilizing effects and has...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1542/peds.2019-1035

データ提供：米国国立医学図書館（NLM）

Nadolol: A New Oasis in Infantile Hemangioma Treatment, But With a Few Hidden Thorns

Infantile hemangiomas, benign tumors of blood vessels, can be a source of worry for parents, like a looming sandstorm threatening their child's well-being. This study explores the use of nadolol, a beta-adrenergic antagonist, in the treatment of infantile hemangioma.

Nadolol: A Promising Oasis, But With Potential Risks

The study highlights the potential benefits of nadolol in treating infantile hemangioma, offering a potential alternative to the more commonly used propranolol. However, the authors caution that nadolol's pharmacokinetics and safety in infants are not fully understood, raising concerns about potential toxicity.

Navigating the Desert of Pediatric Drug Safety: A Call for Vigilance

The study emphasizes the importance of careful monitoring and prompt intervention to manage potential adverse effects of nadolol in infants. It also suggests that propranolol may be a safer option overall due to its shorter half-life and different elimination pathways.

Dr.Camel's Conclusion

The desert of pediatric drug safety is a complex landscape. This study serves as a reminder that even seemingly promising medications can have unforeseen consequences. Close monitoring, open communication with healthcare providers, and careful decision-making are crucial for ensuring the safety and well-being of our youngest patients.

Date :
  1. Date Completed 2020-04-08
  2. Date Revised 2020-04-08
Further Info :

Pubmed ID

31852735

DOI: Digital Object Identifier

10.1542/peds.2019-1035

Related Literature

Article Analysis
・Side Effects of nadolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.